

Drug interactions with NOACs

If blank, interaction not documented on SPC.

| Potential drug interaction | | Dabigatran ¹ | Rivaroxaban ² | Apixaban ³ | Edoxaban ⁴ |
|--|--------------|--|--------------------------|-----------------------|-----------------------|
| Antiarrhythmics | Amiodarone | Caution No dosage reduction | | No dose adjustment | No dose reduction |
| | Quinidine | Caution No dose reduction | | No dose adjustment | No dose reduction |
| | Verapamil | Caution Dose reduction to 110mg twice daily | | No dose adjustment | No dose reduction |
| | Dronedarone | Contra-indicated | Avoid | No effect | 30mg daily |
| | Diltiazem | | | No dose adjustment | Not studied |
| | Digoxin | No changes in digoxin or dabigatran observed | | | No dose reduction |
| Antivirals | | Not studied - avoid | Not recommended | | Not studied |
| Antifungals - strong inhibitors of both CYP3A4 and P-gp | Itraconazole | Contra-indicated | Not recommended | Not recommended | |
| | Voriconazole | | Not recommended | Not recommended | |
| | Posaconazole | Caution | Not recommended | Not recommended | |
| | Ketoconazole | Contra-indicated | Not recommended | Not recommended | 30mg daily |

| Potential drug interaction | | Dabigatran ¹ | Rivaroxaban ² | Apixaban ³ | Edoxaban ⁴ |
|----------------------------------|--------------|--|---|--------------------------------|--|
| Antibiotics | Erythromycin | | Increase in rivaroxaban levels not considered clinically relevant. The effect of erythromycin is additive to that of renal impairment | | 30mg daily |
| | Rifampicin | Avoid | | AF – caution DVT/PE - avoid | Caution |
| NSAIDs – increased bleeding risk | | Increased bleeding risk Review benefits vs. risks Consider 110mg twice daily | Caution | Caution – no dose adjustment | Increased bleeding time Chronic use not recommended |
| Antiplatelet | Clopidogrel | Increased bleeding risk Review benefits vs. risks Use 110mg twice daily | Caution | | May increase risk of bleeding |

| Potential drug interaction | | Dabigatran ¹ | Rivaroxaban ² | Apixaban ³ | Edoxaban ⁴ |
|----------------------------|----------------------|--|--------------------------|--------------------------------|--|
| Antiplatelet | Acetylsalicylic acid | Increased bleeding risk. Review benefits vs. risks. Consider 110mg twice daily | Caution | Caution | High dose ASA not recommended. Edoxaban can be co-administered with low dose ASA (≤ 100 mg/day). |
| PPIs | | No reduced efficacy | | | |
| SSRIs/SNRIs | | Increased bleeding risk. Review benefits vs. risks | | | |
| Immunosuppressants | Ciclosporin | Contra-indicated | | | 30mg daily |
| Others | Phenytoin | Avoid | | AF – caution DVT/PE - avoid | Caution |
| | Carbamazepine | Avoid | | AF – caution DVT/PE - avoid | Caution |
| | Phenobarbitone | Avoid | | AF – caution DVT/PE - avoid | Caution |
| | St Johns Wort | Avoid | | AF – caution DVT/PE - avoid | Caution |

References

1. Summary of Product Characteristics - Pradaxa (dabigatran) 110 mg hard capsules, Boehringer Ingelheim Limited. Updated 8/3/16
<https://www.medicines.org.uk/emc/medicine/20760> Accessed 8/9/16
2. Summary of Product Characteristics – Xarelto (rivaroxaban) 15mg film-coated tablets, Bayer plc. Updated 15/08/14.
<https://www.medicines.org.uk/emc/medicine/25592> Accessed 8/9/16
3. Summary of Product Characteristics – Eliquis (apixaban) 2.5 mg film-coated tablets, Bristol-Myers Squibb-Pfizer. Updated 30/07/14. <https://www.medicines.org.uk/emc/medicine/24988>. Accessed 8/9/16
4. Summary of Product Characteristics – Lixiana (edoxaban) 30mg film-coated tablets, Daiichi Sankyo. June 2015.
<https://www.medicines.org.uk/emc/medicine/30512> Accessed 8/9/16